JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

JNJ

227.58

+1.12%↑

ABT

93.81

+1.03%↑

MDT

81.87

-1.27%↓

A

114.85

-0.62%↓

VEEV

158.41

-1.09%↓

Search

Schrodinger Inc

Cerrado

SectorSanidad

12.22 4.18

Resumen

Variación precio

24h

Actual

Mínimo

11.54

Máximo

12.49

Métricas clave

By Trading Economics

Ingresos

169M

136M

Ventas

33M

87M

BPA

-0.18

Margen de beneficios

155.644

Empleados

850

EBITDA

67M

36M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+55.45% upside

Dividendos

By Dow Jones

Próximas Ganancias

5 may 2026

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

118M

945M

Apertura anterior

8.04

Cierre anterior

12.22

Noticias sobre sentimiento de mercado

By Acuity

7%

93%

5 / 348 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Schrodinger Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

27 abr 2026, 23:15 UTC

Noticias de Eventos Importantes

U.K. Consumers Pay Less But Full Impact of Mideast War to Be Seen

27 abr 2026, 23:08 UTC

Ganancias
Principales Movimientos del Mercado

LendingClub Shares Gain on 1Q Profit, Revenue Beat

27 abr 2026, 23:58 UTC

Ganancias

Samsung SDI 1Q Net Profit Beat FactSet-Compiled Consensus

27 abr 2026, 23:58 UTC

Ganancias

Samsung SDI 1Q Net KRW56.10B Vs. Loss KRW216.00B >006400.SE

27 abr 2026, 23:56 UTC

Ganancias

Samsung SDI 1Q Oper Loss KRW155.60B Vs. Loss KRW434.10B >006400.SE

27 abr 2026, 23:56 UTC

Ganancias

Samsung SDI 1Q Rev KRW3.576T Vs. KRW3.177T >006400.SE

27 abr 2026, 23:48 UTC

Charlas de Mercado

Nikkei May Remain Rangebound Amid Uncertainty Over Iran Conflict -- Market Talk

27 abr 2026, 23:42 UTC

Charlas de Mercado

Australian Consumer Confidence Making a Slow Come Back -- Market Talk

27 abr 2026, 23:34 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Gold Edges Higher as Investors Assess Iran's Proposal to U.S. -- Market Talk

27 abr 2026, 23:30 UTC

Charlas de Mercado

Australia's NDIS Could Lose 'Social Licence' If Not Reined In -- Market Talk

27 abr 2026, 23:08 UTC

Charlas de Mercado

Polymetals's Revenue Outlook 'Extraordinary' for a Small-Cap Stock -- Market Talk

27 abr 2026, 23:02 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

27 abr 2026, 23:02 UTC

Charlas de Mercado

Warsh Will Probably Lean a Bit More Dovish Than Powell -- Market Talk

27 abr 2026, 22:42 UTC

Charlas de Mercado

BOJ Expected to Keep Rates On Hold; Guidance to Skew Hawkish -- Market Talk

27 abr 2026, 22:10 UTC

Ganancias

Haier Smart Home: Results Also Weighed by Weak Demand in China-U.S. Markets >600690.SH

27 abr 2026, 22:09 UTC

Ganancias

Haier Smart Home: Increase in Tariff Costs, Extreme Weather Conditions Hurt Results >600690.SH

27 abr 2026, 22:09 UTC

Ganancias

Haier Smart Home 1Q Net CNY4.65B Vs. Net CNY5.49B >600690.SH

27 abr 2026, 22:09 UTC

Ganancias

Haier Smart Home 1Q Rev CNY73.69B Vs. CNY79.12B >600690.SH

27 abr 2026, 21:56 UTC

Ganancias

Tsingtao Brewery: Cost Controls Among Factors Supporting Results >0168.HK

27 abr 2026, 21:55 UTC

Ganancias

Tsingtao Brewery 1Q Net CNY1.80B Vs. Net CNY1.71B >0168.HK

27 abr 2026, 21:55 UTC

Ganancias

Tsingtao Brewery 1Q Rev CNY10.29B Vs. CNY10.45B >0168.HK

27 abr 2026, 21:44 UTC

Ganancias

Tianqi Lithium: Higher Demand for Products From EV Sector Also Boosted Financial Performance >002466.SZ

27 abr 2026, 21:43 UTC

Ganancias

Tianqi Lithium: Increase in Average Selling Prices of Major Lithium Products Supported Results >002466.SZ

27 abr 2026, 21:41 UTC

Ganancias

Tianqi Lithium 1Q Rev CNY5.13B Vs. CNY2.58B >002466.SZ

27 abr 2026, 21:41 UTC

Ganancias

Tianqi Lithium 1Q Net CNY1.88B Vs. Net CNY104.27M >002466.SZ

27 abr 2026, 20:50 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

27 abr 2026, 20:50 UTC

Charlas de Mercado
Noticias de Eventos Importantes

Basic Materials Roundup: Market Talk

27 abr 2026, 20:50 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

Financial Services Roundup: Market Talk

27 abr 2026, 20:50 UTC

Charlas de Mercado

Health Care Roundup: Market Talk

27 abr 2026, 20:39 UTC

Ganancias

Nucor: Operating Segments Earnings Growth Driven by Trade Policies That Continue to Reduce Flood of Unfairly Traded Imports Into U.S. >NUE

Comparación entre iguales

Cambio de precio

Schrodinger Inc previsión

Precio Objetivo

By TipRanks

55.45% repunte

Estimación a 12 Meses

Media 18.25 USD  55.45%

Máximo 20 USD

Mínimo 13 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Schrodinger Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

4

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.13Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Very Strong Bullish Evidence

Sentimiento

By Acuity

5 / 348 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Coyuntura alcista notoria

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat